Entries by Healthcare Team

New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources

/in

The Novo Nordisk Foundation Challenge Programme supports development of new knowledge to help tackle major societal challenges within human and planetary health. With total funding up to €80 million, four new themes are now open for applications from interdisciplinary research teams across Europe. From the way we diagnose disease to how we produce chemicals and […]

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

/in

Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1.3 patency‑related reintervention rate per patient year) and a 3% clinically relevant access related infection rate CE mark approval enables Xeltis to […]

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

/in

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess™ reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN, The Netherlands – 21 April, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

/in

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tumor immune response to benefit cancer patients in need   Lund, Sweden, 17 April 2026 – Asgard Therapeutics, a privately held biotech company pioneering […]